StockData

Amphastar Pharmaceuticals, Inc. (AMPH) stock

AMPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3013% below fair value
$29.71+0.61 (+2.10%)

Close on Nov 18, 2026Market cap $1.26BP/E 17.5Yield –

Amphastar Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Amphastar Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was $152.89M, up 36.3% year over year. For fiscal 2025 it was $121.23M, down 29.7% from the year before. The highest annual figure on record is $172.35M in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$121.23M-29.7%
FY2024Dec 31, 2024$172.35M+18.6%
FY2023Dec 31, 2023$145.34M+123.1%
FY2022Dec 31, 2022$65.15M-7.6%
FY2021Dec 31, 2021$70.54M+201.3%
FY2020Dec 31, 2020$23.41M+11209.7%
FY2019Dec 31, 2019$207.00K–
FY2018Dec 31, 2018-$8.62M-309.7%
FY2017Dec 31, 2017$4.11M-76.1%
FY2016Dec 31, 2016$17.18M–
FY2015Dec 31, 2015-$5.32M-1061.1%
FY2014Dec 31, 2014$553.00K-95.9%
FY2013Dec 31, 2013$13.40M–
FY2012Dec 31, 2012-$24.78M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$42.73M+70.7%
Q1 FY2026Mar 31, 2026$38.33M+57.2%
Q4 FY2025Dec 31, 2025$24.59M+48.0%
Q3 FY2025Sep 30, 2025$47.24M+2.3%
Q2 FY2025Jun 30, 2025$25.03M-60.3%
Q1 FY2025Mar 31, 2025$24.38M-47.6%
Q4 FY2024Dec 31, 2024$16.61M+15.2%
Q3 FY2024Sep 30, 2024$46.17M-14.7%
Q2 FY2024Jun 30, 2024$63.07M+37.5%
Q1 FY2024Mar 31, 2024$46.50M+50.5%
Q4 FY2023Dec 31, 2023$14.42M+61.8%
Q3 FY2023Sep 30, 2023$54.14M+267.0%
Q2 FY2023Jun 30, 2023$45.87M–
Q1 FY2023Mar 31, 2023$30.91M-30.7%
Q4 FY2022Dec 31, 2022$8.92M-73.4%
Q3 FY2022Sep 30, 2022$14.75M–
Q2 FY2022Jun 30, 2022-$3.15M-111.9%
Q1 FY2022Mar 31, 2022$44.63M+193.5%
Q4 FY2021Dec 31, 2021$33.56M+343.7%
Q3 FY2021Sep 30, 2021-$4.65M-246.4%
Q2 FY2021Jun 30, 2021$26.42M+37.6%
Q1 FY2021Mar 31, 2021$15.21M–
Q4 FY2020Dec 31, 2020$7.56M–
Q3 FY2020Sep 30, 2020$3.18M–
Q2 FY2020Jun 30, 2020$19.20M-54.3%
Q1 FY2020Mar 31, 2020-$6.53M–
Q4 FY2019Dec 31, 2019-$2.76M–
Q3 FY2019Sep 30, 2019-$20.68M-757.4%
Q2 FY2019Jun 30, 2019$42.00M–
Q1 FY2019Mar 31, 2019-$18.35M–
Q4 FY2018Dec 31, 2018-$65.00K–
Q3 FY2018Sep 30, 2018$3.15M–
Q2 FY2018Jun 30, 2018-$7.72M–
Q1 FY2018Mar 31, 2018-$3.98M-126.3%
Q4 FY2017Dec 31, 2017-$353.00K-104.1%
Q3 FY2017Sep 30, 2017-$8.94M–
Q2 FY2017Jun 30, 2017-$1.73M–
Q1 FY2017Mar 31, 2017$15.13M–
Q4 FY2016Dec 31, 2016$8.67M–
Q3 FY2016Sep 30, 2016-$5.40M–

More Amphastar Pharmaceuticals figures

See a number that looks wrong?